ONL Therapeutics

IN THE PRESS

Press Releases

ONL Therapeutics Closes $65 Million in Oversubscribed Series D Financing

September 13, 2024

·

3 min read

Press Releases

ONL Therapeutics to Present at the 57th Annual Scientific Meeting of The Retina Society and EURETINA Innovation Spotlight

September 10, 2024

·

2 min read

BioMidwest

ONL Therapeutics to Present at 2024 BIO CEO & Investor Conference

February 6, 2024

·

1 min read

BioMidwest

ONL Therapeutics to Present on ONL1204 in Podium Presentation at the 47th Annual Meeting of the Macula Society

January 23, 2024

·

3 min read

Drug Development

ONL Therapeutics Completes Enrollment in Phase 2 Study of First-in-Class Fas-Inhibitor in Patients with Macula-Off Rhegmatogenous Retinal Detachment

August 28, 2023

·

3 min read

Drug Development

ONL Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of First-in-Class Fas-Inhibitor in Patients with Macula-Off Rhegmatogenous Retinal Detachment

April 12, 2023

·

2 min read

BioMidwest

ONL Therapeutics Closes First Tranche of $15 Million Series C Financing to Advance Lead Compound into Phase 2 Clinical Trial

March 8, 2023

·

3 min read

BioMidwest

ONL Therapeutics to Present at 2023 BIO CEO & Investor Conference

February 2, 2023

·

1 min read

BioMidwest

ONL Therapeutics to Highlight New Data in Upcoming Scientific Presentations at the 46th Annual Macula Society Meeting and the XXVth Biennial Meeting of the International Society for Eye Research

January 26, 2023

·

2 min read

Drug Development

AmbioPharm Supports ONL Therapeutics with Peptide Manufacturing to Prepare for IND Application for Phase 2 Study

July 12, 2022

·

3 min read

JOBS